Drug Trial Radar · NCT02095626
Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation
Last checked: Nov 19, 2026Latest source record: Nov 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jun 2013
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- Apeptico Forschung und Entwicklung GmbHIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the effect of orally inhaled AP-301 on primary graft dysfunction after lung transplantation.
Conditions
- PGD Primary Graft Dysfunction
Interventions
AP-301Drug
orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
saline solutionDrug
placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- P/F ratioTime frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Thoracic Surgery MedUni Vienna
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.